← All trials
NCT01996436
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2016
- Primary completion
- Aug 1, 2018
- Completion date
- Dec 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 330
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- University of Texas at HoustonLead sponsor
- University of Texas at HoustonOverall official - principal investigator
- Yale UniversityOverall official - principal investigator
- Yale UniversityCollaborator
- Thomas Jefferson UniversityCollaborator
- Mayo ClinicCollaborator
- Temple UniversityCollaborator
- Geisinger ClinicCollaborator
- Northwell HealthCollaborator
- University of MichiganCollaborator
- Lenox Hill HospitalCollaborator
- Wake Forest UniversityCollaborator
- University of Texas at HoustonReponsible party - principal investigator
- Harvard UniversityCollaborator
- State University of New York, BuffaloCollaborator
- University of Illinois at ChicagoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.